Prospective Double-blind Randomized Study to Evaluate Lucentis for Prophylaxis Against the Conversion to Neovascular Age-related Macular Degeneration (AMD) in High-risk Eyes (Let's ProTECT AMD Eyes)

Trial Profile

Prospective Double-blind Randomized Study to Evaluate Lucentis for Prophylaxis Against the Conversion to Neovascular Age-related Macular Degeneration (AMD) in High-risk Eyes (Let's ProTECT AMD Eyes)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Age-related macular degeneration; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms PROTECT
  • Most Recent Events

    • 18 Oct 2016 Planned number of patients changed from 88 to 4.
    • 18 Oct 2016 Planned End Date changed from 1 Nov 2017 to 1 Jul 2017.
    • 18 Oct 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top